Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Diabetes Obes MetabJul 30, 2026 (epub)
Chuhan Shao, Hanmo Lin, Jie Yu et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of bimagrumab in 268 adults with obesity and metabolic dysfunction. The results indicated that bimagrumab significantly reduced total weight by 4.85 kg and fat mass by 4.72 kg compared to placebo, while also improving glycated hemoglobin levels. However, it was associated with increased LDL levels and higher rates of adverse events.
Key findings
- Bimagrumab reduced total weight by 4.85 kg compared to placebo.
- Fat mass decreased by 4.72 kg with bimagrumab treatment.
- Glycated hemoglobin levels improved by 0.13% with bimagrumab.
- Bimagrumab increased LDL concentrations by 0.47 mmol/L.
Why it matters
The findings suggest that bimagrumab may be an effective treatment option for adults with obesity and metabolic dysfunction, potentially improving body composition and glycemic control. Understanding its safety profile is crucial for clinical decision-making.